Search POM Topics

Direct Link to ADS-ANZCA 2022 Perioperative Diabetes Guideline HERE

Pre-Operative HbA1c Targets

  • HbA1c should be measured < 3 months (preferably 4-6 weeks) prior to elective surgery.
  • Refer to endocrinologist when HbA1c is ≥ 9% or when there is hypoglycaemia unawareness.
  • Target HbA1c < 9% prior to elective surgery.
    • Patients with HbA1c > 9% have poorer outcomes and the ADS-ANZCA Guidelines recommend delaying elective surgery to obtain better glycaemic control.
    • This delay may be 1-2 weeks in urgent surgery settings, or 3 months in less urgent settings.

Screening of Patients Without Known Diabetes

  • Up to 30% of patients may have undiagnosed diabetes
  • Screen with:
    • HbA1c prior to Major Surgery
    • random BGL prior to Minor Surgery
  • Refer to GP for further management if HbA1c > 6.5% or random BGL > 12mmol/L.
  • Perioperative management should proceed as if patient has diabetes
Planned Surgery Undiagnosed Diabetic Screening
Major HbA1c
Minor Random BGL

Perioperative Diabetic Medication Management

Perioperative Diabetic Medication Management1

Oral Antihyglycaemic Medication Management

Class Examples Day Prior to Surgery Day of Surgery
Sulphonylureas

gliclazide (diamicron)
glipizide (glucotrol)
glimepride (amaryl)
glyburide (glynase)

Continue as Usual Withhold
Alpha-glucosidase Inhibitors Acarbose
DPP-IV Inhibitors

linagliprin (Trajenta)
sitagliptin (Januvia)
alogliptin (Nesina)
saxagliprin (Onglyzna)
vildagliptin (Galvus)

Thiazolidinediones

rosiglitazone (Avandia)
pioglitazone (Actos)

Biguanides

metformin
metformin + sinagliptin (Janumet)

SGLT2is

dapagliflozin (Forxiga)
empagliflozin (Jardiance)
rrtugliflozin (Steglatro)
dapagliflozin + metformin (Xigduo)

Major Surgery / Colonoscopy
Cease 2 days prior + day of surgery
last dose day -3

Day Surgery / Gastroscopy
Cease Day of Surgery

GLP-1 Analogues

semaglutide (Ozempic)
liraglutide (Saxenda)

Continue as usual

Follow 24-hour fasting guideline
- clear fluids only for 24 hours prior
- water only on DOS
- NBM 2 hours pre-op

Click HERE to View Patient Information Handout
Class
Sulphonylureas
gliclazide (diamicron)
glipizide (glucotrol)
glimepride (amaryl)
glyburide (glynase)
Day Prior to Surgery Day of Surgery
Continue as Usual Withhold
Alpha-glucosidase Inhibitors
acarbose
Day Prior to Surgery Day of Surgery
Continue as Usual Withhold
DPP-IV Inhibitors
linagliprin (Trajenta)
sitagliptin (Januvia)
alogliptin (Nesina)
saxagliprin (Onglyzna)
vildagliptin (Galvus)
Day Prior to Surgery Day of Surgery
Continue as Usual Withhold
Thiazolidinediones
rosiglitazone (Avandia)
pioglitazone (Actos)
Day Prior to Surgery Day of Surgery
Continue as Usual Withhold
Biguanides
metformin
metformin + sinagliptin (Janumet)
Day Prior to Surgery Day of Surgery
Continue as Usual Withhold
SGLT2is
dapagliflozin (Forxiga)
empagliflozin (Jardiance)
Ertugliflozin (Steglatro)
dapagliflozin + metformin (Xigduo)
Day Prior to Surgery Day of Surgery
Major Surgery / Colonoscopy
Cease 2 days prior + day of surgery
last dose day -3

Day Surgery / Gastroscopy
Cease Day of Surgery
Withhold
GLP-1 Analogues
semaglutide (Ozempic)
liraglutide (Saxenda)
Day Prior to Surgery Day of Surgery
Continue as usual

Follow 24-hour fasting guideline
- clear fluids only for 24 hours prior
- water only on DOS
- NBM 2 hours pre-op

Click HERE to View Patient Information Handout

SGLT2i: Sodium-glucose cotransporter 2, DPP-IV: Dipeptidyl peptidase IV, GLP-1: glucagon-like peptide
* Major surgery: surgical cases requiring > 1 night of hospitalisation post-operatively
* Minor surgery: all day surgical cases and extended day surgery cases that require 1 night in hospital

Insulin Management

Type
Basal Insulin Only
Insulin glargine
• Lantus
• Optisulin
• Tuojeo
• Semglee

Insulin determir
• Levemir
AM List PM List
No dose change No dose change
Basal Bolus Regime
Basal
• Insulin glargine
• Insulin detemir

Bolus
Ultrarapid: Aspart-FiAsh
Rapid: humalog, novorapid, apidra
Short: actrapid, Humulin R
AM List PM List
Omit the morning and lunch time rapid/short-acting insulin.

Keep basal dose unchanged
Give 50% morning rapid/short-acting insluin with a light breakfast.

Omit lunch time dose (fasting)

Keep basal and evening meal dose unchanged if eating.
Pre-Mixed
(intermediate + short/rapid)
• Novomix 30
• Mixtard 30/70
• Humalog mix 25
AM List PM List
Give 50% usual morning dose

Omit any lunchtime dose if not eating

Leave the evening meal dose unchanged.
Give 50% usual dose with breakfast

Omit any lunchtime dose

Leave evening dose unchanged if eating.
Co-Formulated
(ultra-long + rapid)
• Ryzodeg 70/30
AM List PM List
Omit on morning of surgery for morning procedure

Give usual morning dose at lunchtime if able to eat by then

If patient is on morning or lunchtime only dose, give usual dose with evening meal if not able to eat before then.
Give 50% usual morning dose with light breakfast

Omit any usual lunchtime doses

If usually lunchtime dose only, give usual dose with evening meal, if eating by then

If usually takes evening dose, give usual dose with evening meal if eating.
Intermediate Acting Insulin with 2-3 Rapid-Acting or Short-Acting Insulin Doses For Meals
• Humulin NPH
• Protaphane
AM List PM List
Calculate the total dose of all insulins for the morning and lunch.

50% of the total insulin dose should be given as an Intermediate acting insulin only in the morning

Leave evening meal and pre-bed doses unchanged.
Calculate the total dose of all insulins for the morning and lunch.

50% of the total insulin dose should be given as an Intermediate acting insulin only in the morning

Half the morning rapid-acting insulin can be given with a light breakfast.

Leave evening meal and pre-bed doses unchanged.
Subcutaneous Insulin Pump
AM List PM List
Continue basal infusion at usual rates

OR

Use temporary basal rate of 80% usual if:

• fasting BGL < 5mmol/L

• HbA1c < 58mmol/mol (6.5%)


If Autopump mode, set exercise blood glucose target
50% calculated bolus at breakfast

Continue basal infusion at usual rates

OR

Use temporary basal rate of 80% usual if:

• fasting BGL < 5mmol/L

• HbA1c < 58mmol/mol (6.5%)


If Autopump mode, set exercise blood glucose target
Type Examples AM List PM List
Basal Insulin Only Insulin glargine
• Lantus
• Optisulin
• Tuojeo
• Semglee

Insulin determir
• Levemir
No dose change No dose change
Basal Bolus Regime Basal
• Insulin glargine
• Insulin detemir

Bolus
Ultrarapid: Aspart-FiAsh
Rapid: humalog, novorapid, apidra
Short: actrapid, Humulin R
Omit the morning and lunch time rapid/short-acting insulin.

Keep basal dose unchanged
Give 50% morning rapid/short-acting insluin with a light breakfast.

Omit lunch time dose (fasting)

Keep basal and evening meal dose unchanged if eating.
Pre-Mixed
(intermediate + short/rapid)
• Novomix 30
• Mixtard 30/70
• Humalog mix 25
Give 50% usual morning dose

Omit any lunchtime dose if not eating

Leave the evening meal dose unchanged.
Give 50% usual dose with breakfast

Omit any lunchtime dose

Leave evening dose unchanged if eating.
Co-Formulated
(ultra-long + rapid)
• Ryzodeg 70/30 Omit on morning of surgery for morning procedure

Give usual morning dose at lunchtime if able to eat by then

If patient is on morning or lunchtime only dose, give usual dose with evening meal if not able to eat before then.
Give 50% usual morning dose with light breakfast

Omit any usual lunchtime doses

If usually lunchtime dose only, give usual dose with evening meal, if eating by then

If usually takes evening dose, give usual dose with evening meal if eating.
Intermediate Acting Insulin with 2-3 Rapid-Acting or Short-Acting Insulin Doses For Meals • Humulin NPH
• Protaphane
Calculate the total dose of all insulins for the morning and lunch.

50% of the total insulin dose should be given as an Intermediate acting insulin only in the morning

Leave evening meal and pre-bed doses unchanged.
Calculate the total dose of all insulins for the morning and lunch.

50% of the total insulin dose should be given as an Intermediate acting insulin only in the morning

Half the morning rapid-acting insulin can be given with a light breakfast.

Leave evening meal and pre-bed doses unchanged.
Subcutaneous Insulin Pump Typically:
• NovoRapid
• Apidra
• Fiasp
Continue basal infusion at usual rates

OR

Use temporary basal rate of 80% usual if:

• fasting BGL < 5mmol/L

• HbA1c < 58mmol/mol (6.5%)


If Autopump mode, set exercise blood glucose target
50% calculated bolus at breakfast

Continue basal infusion at usual rates

OR

Use temporary basal rate of 80% usual if:

• fasting BGL < 5mmol/L

• HbA1c < 58mmol/mol (6.5%)


If Autopump mode, set exercise blood glucose target

* Reduce basal insulin dose by 20% if recent overnight hypoglycaemia

Insulin Pump Management

Day Prior to Procedure Day of Surgery Post Op
Perform a line and set change 24 hours before surgery and record all BGL checks to ensure pump is functioning normally.

The insertion site should be moved to a site distant from surgical site.
If planned eating + drinking post op:
• Contnue basal infusion via pump introp
• If HbA1c <6.5% or if fastng BSL < 5mmol/L set a temporary basal rate of 80% basal intraop.

If nil by mouth post op:
• Cease pump
• Commence insulin-glucose infusion intraop.
Continue at Usual Rates

Bowel Prep

  • Monitor BSL q2h
  • Withhold SGLT2is 2 days pre-procedure plus day of procedure
  • Patients on Insulin Receiving Bowel Preparation Need Changes to Insulin Management
Type Morning of Bowel Prep Evening of Bowel Prep
Basal Bolus Withhold Rapid Acting
Continue Long Acting
Withhold Rapid Acting
Give 50% Long Acting
Intermediate +/- Rapid Acting Calculate Total Morning Dose and Give 50% as Intermediate Acting

Withhold Rapid Acting
Pre-Mixed Insulin Give 50% Usual Dose
Co-Formulated Insulin Give 50% Usual Dose

Variable Rate Insulin Infusions

  • Criteria to cease (all must be met)
    • There is no evidence of diabetic ketoacidosis
    • Tolerating 50% of normal oral intake/ commenced enteral feeds/ TPN
    • Usual diabetes therapies have been resumed
    • Management plan for glycaemic control has been implemented
  • Time to cease
    • Ideally cease afer breakfast, with a dose of oral anti-hyperglycaemic medication having been given before breakfast.

Available Forms of Insulin in Australia

Types of Insulin
Brand name Type
Mealtime or prandial insulins
Ultra rapid-acting

Onset in 5–10 minutes, peak at 30 minutes, duration for 3.5–4 hours
FiAsp Faster insulin aspart
Rapid-acting

Onset in 15–20 minutes, peak at one hour, duration for 3.5–4.5 hours
Humalog Insulin lispro
NovoRapid Insulin aspart
Apidra Insulin glulisine
Short-acting

Onset in ~1 hour, peak at two to five hours, duration for six to eight hours
Actrapid Neutral
Humulin R
Basal insulins
Intermediate-acting
Humulin NPH Isophane
Protaphane
Levemir Insulin detemir

Onset in three to four hours, peak at three to eight hours, duration for 20–24 hours
Optisulin   Insulin glargine (U100)

Onset in one to two hours, flat, duration for 18–24 hours
Semglee
Toujeo Insulin glargine (U300)

Onset in one to two hours, flat, duration for 24–36 hours
Premixed insulins
Humalog Mix 25 Lispro 25%/lispro protamine 75%

Onset in 15–20 minutes, peak at one hour, duration for 14–24 hours
Humalog Mix 50 Lispro 50%/lispro protamine 50%

Onset in 15–20 minutes, peak at one hour, duration for 14–24 hours
NovoMix 30 Insulin aspart 30%/insulin aspart protamine 70%

Onset in 15–20 minutes, peak at one hour, duration for 14–24 hours
Humulin 30/70 Neutral 30%/isophane 70%

Onset in one to two hours, peak at two to five hours, duration for 12–18 hours
Mixtard 30/70
Mixtard 50/50 Neutral 50%/isophane 50%

Onset in one to two hours, peak at two to five hours, duration for 12–18 hours
Ryzodeg 70/30 Insulin degludec 70% and insulin aspart 30%

Onset in 5–20 minutes, peak at one hour, duration for 36–48 hours

Perioperative SGLT2i Management

Perioperative SGLT2i Management2

  • BSL and ketones should be checked on admission
  • Ketones > 1mmol/L should have an urgent VBG to measure base excess
  • euDKR is diagnosed if base excess is < -5mol and ketones > 1mmol/L
Ketones Base Excess Comments
<1 > -5 No Ketosis and No Metabolic Acidosis
• Consider proceeding with day surgery
• Hourly monitoring of blood ketones during the procedure and 2 hourly following the procedure until eating and drinking normal or discharged.

• Where blood gas analysis is not available proceed only if added risk is consistent with goals of care.

More extensive surgery: Consider goals of care and collaboration with endocrinology and critical care.

• Perioperative insulin and glucose infusion may reduce risk.
>1 > -5 Ketosis Without Metabolic Acidosis
• Seek endocrinology or general medicine advice. Ketosis without acidosis may reflect starvation, particularly individuals with HbA1c < 9% (< 75mmol/mol).

• Consider proceeding, but with perioperative insulin and glucose infusion to reduce risk of ketoacicosis.
< -5 Ketosis With Metabolic Acidosis
• Postpone non-urgent surgery.
• Escalate care with Endocrinology and Critical Care.

URGENT surgery to proceed with insulin and glucose infusion and ketone monitoring with guidance from endocrinology and/or critical care.
Footnote: Blood gas analysis is recommended to assess for presence of metabolic acidosis. Where blood gas analysis is not readily available and the ketones are > 1.0mmol/L, the procedure should not be performed.

Perioperative GLP-1 Analogue Management

Perioperative GLP-1 Analogue Management3

  • Cessation of GLP1 analogues is not recommended
  • If any of these agents have been taken within 4 half lives (typically 4 weeks) the patient should be considered at risk of delayed gastric emptying.
  • See ADS / ANZCA Guideline here
  • See Patient Information Handout here
Time Until Procedure Allowed Oral Intake
Minimum 24 hours before procedure

Clear Fluids Only.
(See patient hand out for details)

6 hours before procedure Water only.  Up to 125ml/hr
2 hours before procedure Nil by Mouth

Bedside gastric ultrasound and IV erythromycin may have a role as outline below.

Clinical Practice Recommendations regarding patients taking GLP-1 receptor agonists and dual GLP-1/GIP receptor co-agonists prior to anaesthesia or sedation for surgical and endoscopic procedures (April 2025)  Source

General Intraoperative Glycaemic Management

Pre-Operative

  • Monitor BSL hourly when fasting
  • Treat hypoglycaemia and hyperglycaemia as per below

Intra-Operative

  • Monitor BSL hourly
  • Consider treating hyperglycaemia when BSL > 10mmol/L with subcutaneous insulin
  • Consider commencing variable rate insulin infusion (VRII) when BSL > 12mmol/L
  • Blood gas and ketones should be measured when BSL > 15mmol/L to check for ketoacidosis
Fluid management
  • Isotonic solutions: 0.9% saline, Hartmanns, Plasmalyte can be used for hydration
  • Glucose containing solutions should only be used for the treatment of hypoglycaemia or when using an insulin infusion.
Antiemetics
  • Dexamethasone: where possible it is recommended to use other antiemetics due to glucocorticoid induced hyperglycaemia.
Suggested algorithm for intra-operative hyperglycaemia from the ADS-ANZCA Perioperative Diabetes and Hyperglycaemic Guidelines (adult)

Post-Operative

Monitor BSL hourly until patient leaves PACU
  • If BSL has been stable, monitoring can be decreased to Q2H for type 1 diabetics, and Q2-4H for type 2 diabetics.
Restart usual medications when eating and drinking.
  • Exceptions:
    • Metformin: Patents with CKD 3B / eGFR < 45: recommence when renal functon returned to baseline.
    • SGLT2i
      • Major surgery: Withhold for at least 2 days
      • Minor surgery: Recommence day after surgery
      • Should only be recommenced once eating full diet.

Hyperglycaemia and Hypoglycaemia Management

Hyperglycaemia Management

  • Hyperglycaemia should be treated when BSL >12mmol/L
  • Repeat correctional insulin should not usually be administered within 3 hours of each other.
  • E.g. if a patient is on a total of 50 units of insulin per day the ISF = 2, ie, One unit of insulin is anticipated to lower the BSL by 2mmol/L.
Type I Diabetes
  • Determine correctional insulin doses based on patients’ usual insulin sensitvity factor (ISF)
  • ISF is an approximate amount by which 1 unit of insulin will lower the BSL (in mmol/L)
  • Estimating initial ISF for insulin treated patients: ISF = 100/ total daily insulin dose.
  • E.g. if a patient is on a total of 50 units of insulin per day the ISF = 2, ie, One unit of insulin is anticipated to lower the BSL by 2mmol/L.

Insulin Correction Dose

Insulin Sensitivity ≈ 100TDD

In the absence of known TDD,  a rough estimate of TDD can be made from:

TDD ≈ Body Weight (kg) x 12

Be conscious of risk of ‘insulin stacking‘.  A single rapid acting insulin dose may last 3-5 hours, and repeat insulin doses in that interval may risk over correction.

Type II and Other Forms of Diabetes
  • If >100kg, give 6 units Q3hr until BSL < 12mmol/L
  • If 55-100kg, give 4 units Q3hr until BSL < 12mmol/L
  • If < 55kg, give 2 units Q4hr until BSL <12mmol/L

Hypoglycaemia Management

  • BSL < 4.0mmol/L should be avoided
  • Treatment to avoid hypoglycaemia should begin when BSL < 5.0mmol/L

  • BSL targets:
    • General: 5-10 mmol/L
    • Pregnancy: 5.0 ± 1.0 mmol/L
    • Emergency surgery with poor glycaemic control: 10.0 ± 2.5 mmol/L
    • Known hypoglycaemia unawareness: 10.0 ± 2.5 mmol/L

  • Treatment of hypoglycaemia
    • If >2 hours prior to surgery: clear apple juice
    • If < 2 hours prior to surgery: 25-50ml 50% glucose
Flowchart for management of hypoglycaemic from Canberra Health Sercices Guideline: Diabetes Management: Including hypoglycaemia, IV insulin infusions and insulin pumos (Adults only). 20214
5 6 7 8 9

References

  1. ADS-ANZCA Perioperative Diabetes and Hyperglycaemia Guidelines (Adult) - November 2022
  2. Periprocedural Diabetic Ketoacidosis (DKA) with SGLT2 Inhibitor Use in People with Diabetes. ALERT UPDATE JULY 2022. ADS / ANZCA
  3. Clinical Practice Recommendations regarding patients taking GLP-1 receptor agonists and dual GLP-1/GIP receptor co-agonists prior to anaesthesia or sedation for surgical and endoscopic procedures - ADS / ANZCA
  4. Diabetes Management Including Hypoglycaemia, IV Insulin Infusions and Insulin Pumps (Adults only)
  5. Perioperative Management of the Surgical Patient with Diabetes – Anaesthesia 2015
  6. AAGBI - Peri‐operative management of the surgical patient with diabetes - Anaesthesia 2015
  7. Management of diabetes and hyperglycaemia in the hospital - Lancet Diabetes Educational 2021
  8. NHS - Peri-Operative Management of Diabetes in Adults - 2018
  9. Perioperative Hyperglycemia Management - An Update - Anesthesiology 2017
Topic Contents